Sequent Scientific (SEQUENT) | Stock Overview & Key Data
Sequent Scientific Performance Comparison
Stock Range
Today's Range
Low: ₹167.10
High: ₹184.00
on August 8, 2025
52 Week Range
Low: ₹117.35
High: ₹240.70
on April 7, 2025
on October 1, 2024
All-Time High: ₹336.50 on June 28, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR44.8B
EPS
0.85
P/E Ratio (TTM)
210.48
Forward P/E
35.43
P/B Ratio
6.35
PEG Ratio
35.43
Div. Yield
N/A
ROE
4.35%
Beta
0.913
Debt to Equity
62.47
Financial Highlights
Profitability
Gross Margin
50.28%
Operating Margin
9.41%
Profit Margin
1.41%
Returns and Earnings
Return on Assets (TTM)
4.01%
Return on Equity (TTM)
4.35%
EBITDA
INR1.7B
Net Income (TTM)
INR218.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR62.08
Quarterly Revenue Growth (YoY)
11.20%
Quarterly Earnings Growth (YoY)
12.28%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sequent Scientific SEQUENT | 44.76B Small-cap | -0.34% | -9.41% | 8.30% | 7.32% | -9.00% | 22.29% | 57.12% | 26.68% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Sun Pharma Advanced SPARC | 48.23B Small-cap | -4.83% | -8.86% | 0.02% | -8.70% | -28.94% | -34.79% | -34.46% | -20.13% |
| Aarti Drugs AARTIDRUGS | 44.83B Small-cap | 0.47% | 3.52% | 17.71% | 21.40% | 7.96% | -1.73% | 18.09% | -4.28% |
| Orchid Pharma ORCHPHARMA | 40.61B Small-cap | -2.89% | 3.98% | -3.82% | -42.10% | -58.88% | -51.82% | 152.39% | 13,751.38% |
Ownership & Short Interest
Insider Ownership
52.86%
Institutional Ownership
12.70%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
414K
Average 90-Day Volume
471K
Sequent Scientific Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sequent Scientific would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SEQUENT's 52-week high and low?
- In the last 52 weeks, Sequent Scientific reached a high of ₹240.70 (on October 1, 2024) and a low of ₹117.35 (on April 7, 2025).
- What is the market cap and P/E ratio for SEQUENT?
- Curious about Sequent Scientific's size and valuation? Its market capitalization stands at 44.76B. When it comes to valuation, the P/E ratio (trailing twelve months) is 210.48, and the forward P/E (looking ahead) is 35.43.
- Does SEQUENT pay dividends? If so, what's the yield?
- As for dividends, Sequent Scientific isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sequent Scientific's main competitors or similar companies to consider before investing?
When looking at Sequent Scientific, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Sun Pharma Advanced
SPARC48.23B Healthcare Drug Manufacturers - Specialty & Generic -34.79% -34.46% Aarti Drugs
AARTIDRUGS44.83B Healthcare Drug Manufacturers - Specialty & Generic -1.73% 18.09% Orchid Pharma
ORCHPHARMA40.61B Healthcare Drug Manufacturers - Specialty & Generic -51.82% 152.39% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sequent Scientific Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sequent Scientific's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.35%, the Debt to Equity ratio from the most recent quarter is 62.47, and its Gross Profit Margin stands at 50.28%.
- What is the recent revenue and earnings growth for SEQUENT?
- Looking at Sequent Scientific's growth, its revenue over the trailing twelve months (TTM) was INR16B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.20%, and quarterly earnings saw a YoY growth of 12.28%.
- How much of SEQUENT stock is held by insiders and institutions?
- Wondering who owns Sequent Scientific stock? Company insiders (like executives and directors) hold about 52.86% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 12.70%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.